Goldman Sachs just put a buy rating on this ASX 50 share

This blue chip could be a top option according to one broker.

| More on:
A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Computershare Ltd (ASX: CPU) share price is pushing higher on Monday despite the market weakness.

In afternoon trade, the ASX 50 administration services company's shares are up 0.5% to $23.64.

This compares favourably to a 0.6% decline by the ASX 200 index.

Why is this ASX 50 share rising?

Today's gain appears to have been driven by a broker note out of Goldman Sachs this morning.

According to the note, the broker has initiated coverage on Computershare's shares with a buy rating and a $27 price target.

This implies a potential upside of 14% for investors over the next 12 months.

Goldman is also forecasting a 5.2% dividend yield in FY 2024, increasing the total potential return to over 19%.

What did the broker say?

Goldman named five reasons why it has just put a buy rating on this ASX 50 share.

This includes its potential to outperform guidance, strong balance sheet, and undemanding valuation compared to long-term multiples. It explains:

1) We see upside to FY24 management EPS guidance of 116cps. 2) CPU's Balance sheet is strong and expected to improve further with margin income and FCF despite below the line costs. 3) FY24/FY25 margin income to remain strong from cash rates, however, CPU is hedging a large share of its exposure to reduce earnings sensitivity to yields. 4) Core business: CPU's core business ex MI should benefit from a recovery in corporate actions through improved transaction / event based revenues as well as lower cost inflation pressures being flagged by management and cost out. 5) Overall, we think valuation is not demanding at close to 13x FY24E vs longer term average of around 17x.

The Computershare share price is down almost 15% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »